Pleco has successfully created a model system for studying the way sub-toxic accumulation of multiple metals interacts with cancers and chemotherapy. This is the first time such a model has been created. Its significance is in the possibilities it creates for studying chelation therapy in relation to metal-associated cancers such as AML and SCLC, and likely many other types of cancer.

Pleco’s end product is envisaged as a combination of chelators and an antioxidant. Current research efforts focus on testing combinations that may have a reinforcing effect on each other. The specific aim of the cell and animal experiments is to select combinations that remove a set of representative toxic metals while sparing essential metals.

We have developed a diverse pipeline with several combination products in preclinical development. The first combination is currently being tested.

PRODUCT
LEAD
INDICATION
CANDIDATE
SELECTION
PRECLINICAL
DEVELOPMENT
CLINICAL
DEVELOPMENT
PTX-061
LEUKAEMIA
PTX-062
LUNG CANCER
PTX-081
CANCER (OTHER)